| |
|
|
|
|
|
|
|||
|
Blood, 1 February 2005, Vol. 105, No. 3, pp. 1052-1059. Prepublished online as a Blood First Edition Paper on September 21, 2004; DOI 10.1182/blood-2004-06-2149.
Submitted June 7, 2004
Department of Biochemistry, University of Pavia, Pavia, Italy * Corresponding author; email: pspeziale{at}unipv.it.
The bacterium Streptococcus agalactiae is an etiological agent in the pathogenesis of endocarditis in humans. FbsA, a fibrinogen-binding protein produced by this pathogen, is considered to be an important virulence factor. In this present study we provide evidence that S. agalactiae clinical isolates bearing FbsA attach to fibrinogen and elicit a fibrinogen-dependent aggregation of platelets. Mutants of S. agalactiae lacking the fbsA gene lost the ability to attach to fibrinogen and to aggregate platelets. Plasmid-mediated expression of fbsA restored the capability for fibrinogen binding and platelet aggregation in S. agalactiae fbsA mutants, and allowed Lactococcus lactis to interact with fibrinogen and to aggregate human platelets. Moreover, a monoclonal anti-FbsA antibody inhibited bacterial adherence to fibrinogen and S. agalactiae-induced platelet aggregation. Platelet aggregation was inhibited by aspirin, PGE1, the peptide RGDS and the antibody abciximab demonstrating the specificity of platelet aggregation by S. agalactiae and indicating an involvement of integrin GPIIb/IIIa in the induction of platelet aggregation. Aggregation was also dependent on anti-FbsA IgG and could be inhibited by an antibody against the platelet Fc
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2004 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||